Q2 FY2026 EarningsQ2 FY26 outperformed consensus on the top line with revenue of $71.6M vs. $65.5M expected, a 9.32% beat driven by a 43% surge in clonoSEQ test volumes. Despite the revenue beat, GAAP EPS of -$0.25 missed the -$0.13 mean estimate significantly due to a $23.7M one-time loss on debt extinguishment. Excluding this special item, operational performance showed strength with Adjusted EBITDA improving to -$0.7M and MRD segment profitability expanding as the company pivots toward a potential business separation.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Adaptive Biotechnologies(ADPT) the Revenue is 71.55 M (+21.53%), Beat estimate;the EBIT is -15.77 M (+37.01%), Beat estimate;the EPS is -0.25 (-47.06%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.07B21.53%
0.07B11.16%
+0.01B10.37%
EBITExceed expectations
-0.02B37.01%
-0.02B18.39%
+0.00B18.62%
EPSMiss expectations
-0.2547.06%
-0.133621.44%
-0.116468.50%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf